Thymosin Alpha-1
7 articles in this topic.
All Articles
Zadaxin: The Brand Name Thymosin Alpha-1
Zadaxin (thymalfasin) is thymosin alpha-1 approved in 35+ countries for hepatitis B, sepsis, and immune support. Its story, evidence, and global reach.
Thymosin Alpha-1 for Hepatitis B: Clinical Trial Evidence
Thymosin alpha-1 achieved 40.6% sustained virological response in chronic hepatitis B RCTs, with responses that increase after treatment ends and minimal side effects.
Thymosin Alpha-1 as a Vaccine Adjuvant
Thymosin alpha-1 enhances vaccine responses by activating dendritic cells and TLR pathways. Clinical trials show it cut influenza rates from 19% to 6% in the elderly.
Thymosin Alpha-1 in Cancer: Immunotherapy Adjunct Research
Thymosin alpha-1 is being studied as a cancer immunotherapy adjunct. Review of clinical trials in melanoma, lung cancer, and hepatocellular carcinoma.
Thymosin Alpha-1 for Sepsis: Critical Care Data
Thymosin alpha-1 for sepsis has been tested in RCTs enrolling over 1,900 patients. Here is what the trials found about mortality, immune markers, and subgroup effects.
How Thymosin Alpha-1 Matures T-Cells and Immunity
Thymosin alpha-1 activates dendritic cells via TLR signaling, promotes T-cell maturation, and restores immune function in over 11,000 clinical trial patients.